Combination drug therapy for reducing scar tissue formation
    2.
    发明申请
    Combination drug therapy for reducing scar tissue formation 审中-公开
    用于减少瘢痕组织形成的组合药物治疗

    公开(公告)号:US20060286063A1

    公开(公告)日:2006-12-21

    申请号:US11176713

    申请日:2005-07-07

    IPC分类号: A61K38/17 A61K31/787

    摘要: The present invention describes various devices and methods wherein a cytostatic antiproliferative drug, either alone or in combination with other drugs, is placed between internal body tissues to prevent the formation of scar tissue and/or adhesions during healing of a wound or surgical site. Specific devices to achieve this administration include, but are not limited to, a permanent implant or a biodegradable material having an attached antiproliferative drug such as sirolimus. These antiproliferative drugs may be combined with other drugs including, but not limited to, antiplatelets, antithrombotics or anticoagulants. The present invention also contemplates methods to a reduce scar tissue and/or adhesions or adhesion formation at an anastomosis site. In particular, a cytostatic antiproliferative drug is administered to an arteriovenous shunt anastomoses in patients having end-stage renal disease.

    摘要翻译: 本发明描述了各种装置和方法,其中单独或与其它药物组合的细胞生长抑制性抗增生药物被放置在体内组织之间,以防止伤口或手术部位愈合过程中形成瘢痕组织和/或粘连。 实现这种施用的具体装置包括但不限于具有附着的抗增殖药物如西罗莫司的永久性植入物或可生物降解材料。 这些抗增殖药物可以与其他药物组合,包括但不限于抗血小板,抗血栓药或抗凝血剂。 本发明还考虑了在吻合部位减少瘢痕组织和/或粘连或粘连形成的方法。 特别地,在具有终末期肾脏疾病的患者中,将静脉内抗增殖药物施用于动静脉分流吻合。